DBPR22998:A Potent QPCTL (IsoQC) Inhibitor Targeting CD47-SIRP⍺ Axis for Cancer Immunotherapy
The invention describes a potent, orally bioavailable small molecule isoQC inhibitor targeting the CD47-SIRP⍺ immune checkpoint signal. DBPR22998 effectively inhibits isoQC enzyme activity, reducing the binding of CD47 and SIRPα on the surface of tumor cells and the "don＇t eat me" signal. DBPR22998 is best used in combination with monoclonal antibody-targeted drugs or immune checkpoint antibodies to promote antibody-dependent cell phagocytosis and enhance tumor elimination.
National Health Research Institutes (NHRI) is a medical and health research organization in Taiwan, established as a public-funded foundation. Its main research areas include medicine, pharmaceuticals, public health, and other life sciences, as well as related technologies such as vaccine development.
I804339
A Site-Specific B7-H3 Targeting Antibody-Drug Conjugate for Cancer Therapy
DBPR22998:A Potent QPCTL (IsoQC) Inhibitor Targeting CD47-SIRP⍺ Axis for Cancer Immunotherapy
Development of a Mesenchymal Stem Cell Platform for Multi-Gene Precision Delivery: A Novel Strategy for Cross-Cancer Precision Immunotherapy
AI-PRS Assisted Integrative Medicine Decision-Making Platform: Focus on Liver Cancer and Zebrafish Models
Technology maturity：Experiment stage
Exhibiting purpose：Technology transactions
Trading preferences：Exclusive license/assignment
*Organization
*Name
*Phone
*Main Purpose
*Discuss Further
*Job Category
*Overall Rating
*Favorite Area
*Key Tech Focus
*Willing to Receive Updates?
Other Suggestions
Coming soon!